|Bid||16.50 x 1800|
|Ask||0.00 x 2200|
|Day's Range||16.55 - 16.68|
|52 Week Range||12.43 - 20.93|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||20.53|
|Forward Dividend & Yield||0.84 (5.03%)|
|Ex-Dividend Date||Mar 30, 2020|
|1y Target Est||23.88|
BioLife Plasma Services announces the opening of the first plasma collection center in Nebraska.
Bristol Myers Squibb and Exelixis announced Monday that the FDA had granted priority review for their combined treatment for a form of advanced kidney cancer; and BMY stock, EXEL stock rose.
Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Takeda Pharmaceutical Company Limited and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.